Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 8, 2026, 2:49 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 1,231 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Chronic Obstructive Pulmonary Disease - COPD Clear all
Terminated Not applicable Interventional

Heat Waves and the Elderly With COPD

NCT06295523
View directory record Official record
Conditions
COPD, Aging, Hyperthermia
Interventions
Water Spray, Control
Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
65 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 24, 2025 · Synced Oct 8, 2026, 2:49 AM EDT
Withdrawn Phase 4 Interventional

Legend: TRELEGY Real World Chronic Obstructive Pulmonary Disease (COPD) Effectiveness Study

NCT03949842
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Inhaled corticosteroids/long-acting beta2-adrenergic/long-acting muscarinic receptor antagonists, Fluticasone furoate/umeclidinium/vilanterol
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
3
States / cities
Waterbury, Connecticut • Charlotte, North Carolina • Layton, Utah
Source: ClinicalTrials.gov public record
Updated Apr 22, 2020 · Synced Oct 8, 2026, 2:49 AM EDT
Completed Phase 4 Interventional Results available

Efficacy Safety Study of Arformoterol/Tiotropium Combination Versus Either Therapy Alone in Chronic Obstructive Pulmonary Disease (COPD)

NCT00424528
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, Bronchitis, Emphysema
Interventions
Arformoterol Tartrate Inhalation Solution, Tiotropium, Arformoterol and Tiotropium, Placebo
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
45 Years and older
Enrollment
235 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
28
States / cities
Jasper, Alabama • Tucson, Arizona • San Diego, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2012 · Synced Oct 8, 2026, 2:49 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)

NCT01854645
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
GFF MDI, GP MDI, FF MDI, Open-label tiotropium bromide inhalation powder (Spiriva® Handihaler®), Placebo MDI
Drug
Lead sponsor
Pearl Therapeutics, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
2,103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
121
States / cities
Andalusia, Alabama • Anniston, Alabama • Athens, Alabama + 118 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2017 · Synced Oct 8, 2026, 2:49 AM EDT
Not listed Phase 3 Interventional

Continuous Positive Airway Pressure Versus Noninvasive Ventilation in Patients With Overlap Syndrome

NCT01427673
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, Obstructive Sleep Apnea, Overlap Syndrome
Interventions
Bipap procedure
Procedure
Lead sponsor
United States Air Force
Federal
Eligibility
35 Years to 80 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Wpafb, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 1, 2011 · Synced Oct 8, 2026, 2:49 AM EDT
Completed Phase 2 Interventional Results available

Mechanistic Study of the Effect of Itepekimab on Airway Inflammation in Patients With COPD

NCT05326412
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Itepekimab SAR440340
Drug
Lead sponsor
Sanofi
Industry
Eligibility
40 Years to 70 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
7
States / cities
Torrance, California • Denver, Colorado • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 8, 2026, 2:49 AM EDT
Completed Phase 4 Interventional Results available

The ENERGITO® 2 Study Compares 2 Inhaled Medicines for Chronic Obstructive Pulmonary Disease (COPD). One Medicine is a Combination of Tiotropium and Olodaterol (Stiolto®) Taken Using the Respimat® Inhaler and the Other Medicine is a Combination of Fluticasone and Salmeterol Taken Using the Diskus

NCT03240575
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Tiotropium, Olodaterol, Fluticasone propionate, Salmeterol
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
45
States / cities
Jasper, Alabama • Flagstaff, Arizona • Fullerton, California + 40 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2020 · Synced Oct 8, 2026, 2:49 AM EDT
Completed Phase 3 Interventional

A Pilot Study of Montelukast Sodium (Singulair) in Older Adults With Asthma or Chronic Obstructive Pulmonary Disease

NCT00162864
View directory record Official record
Conditions
Asthma, COPD
Interventions
montelukast sodium
Drug
Lead sponsor
Kaiser Permanente
Other
Eligibility
50 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2002
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 24, 2006 · Synced Oct 8, 2026, 2:49 AM EDT
Completed Phase 1Phase 2 Interventional

Real-Time Support for Exercise Persistence in COPD

NCT00373932
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive, COPD, Emphysema, Chronic Bronchitis
Interventions
Coached exercise persistence intervention, Self-Monitored exercise persistence intervention
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
40 Years to 85 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 7, 2009 · Synced Oct 8, 2026, 2:49 AM EDT
Active, not recruiting Phase 1 Interventional

A Study to Investigate GB-0895 in Adults With Mild to Moderate Asthma or COPD

NCT07116889
View directory record Official record
Conditions
Asthma, COPD (Chronic Obstructive Pulmonary Disease)
Interventions
GB-0895 (SC), Placebo (SC)
Biological · Drug
Lead sponsor
Generate Biomedicines
Industry
Eligibility
18 Years to 80 Years
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
6
States / cities
DeLand, Florida • Miami, Florida • Orlando, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced Oct 8, 2026, 2:49 AM EDT
Completed Phase 3 Interventional Results available

Open-Label Assessment of the Albuterol Spiromax® Dry Powder Inhaler (DPI)

NCT01857323
View directory record Official record
Conditions
Asthma, Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Albuterol Spiromax®
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
4 Years and older
Enrollment
317 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
30
States / cities
Phoenix, Arizona • Costa Mesa, California • Huntington Beach, California + 27 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2015 · Synced Oct 8, 2026, 2:49 AM EDT
Recruiting Phase 4 Interventional

Compare the Effects of Nebulizer Versus Inhaler Based Therapy for COPD Using Long-acting Bronchodilators

NCT07133880
View directory record Official record
Conditions
COPD (Chronic Obstructive Pulmonary Disease)
Interventions
umeclidinium 62.5 µg and vilanterol 25 µg, Revefenacin 175 µg, Formoterol 20 µg, Placebo ( Revefenacin and Formoterol ), Placebo DPI
Drug
Lead sponsor
University of Tennessee Graduate School of Medicine
Other
Eligibility
40 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 8, 2026, 2:49 AM EDT
Completed Phase 2 Interventional Results available

The Effect of Chlorhexidine on the Oral and Lung Microbiota in Chronic Obstructive Pulmonary Disease

NCT02252588
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Chlorhexidine, Placebo
Drug · Other
Lead sponsor
University of Minnesota
Other
Eligibility
40 Years to 85 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 29, 2020 · Synced Oct 8, 2026, 2:49 AM EDT
Completed Not applicable Interventional Results available

Efficacy of Inhaling Bronchodilator Medications in Chronic Obstructive Pulmonary Disease

NCT01391559
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
arformoterol, salmeterol
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
60 Years to 90 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Aug 7, 2013 · Synced Oct 8, 2026, 2:49 AM EDT
Completed Phase 3 Interventional

OPUS Study: Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (BY217/M2-111)

NCT00076089
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, COPD
Interventions
Roflumilast
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years and older
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
35
States / cities
Cities in Alabama, Alabama • Cities in Arizona, Arizona • Cities in Arkansas, Arkansas + 32 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2016 · Synced Oct 8, 2026, 2:49 AM EDT
Completed Early Phase 1 Interventional

New Technology to Assess Treatment for Chronic Obstructive Pulmonary Disease (COPD)

NCT02826343
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Xenon129 MRI imaging, Gadolinium MRI, Advair (250mcg/50mcg) one puff twice a day
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 4, 2020 · Synced Oct 8, 2026, 2:49 AM EDT
Completed Not applicable Interventional

Internet Walking Program and Pedometer in Chronic Obstructive Pulmonary Disease

NCT01564043
View directory record Official record
Conditions
COPD, Internet Access
Interventions
website and pedometer
Behavioral
Lead sponsor
VA Boston Healthcare System
Federal
Eligibility
40 Years to 90 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 27, 2012 · Synced Oct 8, 2026, 2:49 AM EDT
Active, not recruiting Not applicable Interventional

Transitional Care Model Evaluation 2020

NCT04212962
View directory record Official record
Conditions
CHF - Congestive Heart Failure, COPD, Pneumonia
Interventions
Transitional care model (TCM), Usual care
Behavioral
Lead sponsor
Mathematica Policy Research, Inc.
Other
Eligibility
65 Years and older
Enrollment
962 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 8, 2026, 2:49 AM EDT
Completed Phase 2 Interventional Results available

Safety and Tolerability of 28 Days Treatment With Glycopyrronium Bromide (NVA237) (100 or 200 µg Once a Day) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

NCT00510510
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
NVA237 100 µg, Placebo, NVA237 200 µg
Drug
Lead sponsor
Novartis
Industry
Eligibility
40 Years and older
Enrollment
281 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
16
States / cities
Glendale, Arizona • Phoenix, Arizona • Wheat Ridge, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated May 21, 2012 · Synced Oct 8, 2026, 2:49 AM EDT
Completed Phase 4 Interventional

Costs & Outcomes of Hospitalization/Treatment With Levalbuterol & Albuterol in Asthma or Chronic Obstructive Pulmonary Disease (COPD) Subjects

NCT00667797
View directory record Official record
Conditions
Asthma, COPD
Interventions
levalbuterol HCl, albuterol Sulfate
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
486 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
18
States / cities
Birmingham, Alabama • Chula Vista, California • Oakland, California + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2012 · Synced Oct 8, 2026, 2:49 AM EDT
Completed No phase listed Observational Results available

Chronic Obstructive Pulmonary Disease (COPD) Dual Therapy Burden of Illness

NCT03543176
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
UMEC/VI, FLUT/SAL, CAT, mMRC, Ellipta, Diskus
Other · Device
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
65 Years and older
Enrollment
789 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 5, 2020 · Synced Oct 8, 2026, 2:49 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Functional Proteomics of Alveolar Macrophages

NCT00806091
View directory record Official record
Conditions
COPD
Interventions
Not listed
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2008
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 8, 2026, 2:49 AM EDT
Completed Phase 4 Interventional Results available

Phase 4 COPD and Suboptimal Inspiratory Flow Rate

NCT05165485
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Revefenacin, Tiotropium, Revefenacin Placebo, Tiotropium Placebo
Drug
Lead sponsor
Theravance Biopharma
Industry
Eligibility
40 Years and older
Enrollment
404 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
76
States / cities
Jasper, Alabama • Phoenix, Arizona • Tucson, Arizona + 67 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2024 · Synced Oct 8, 2026, 2:49 AM EDT
Recruiting Not applicable Interventional

COPD Resources, Education, and Activity Designed for You Study

NCT07125053
View directory record Official record
Conditions
COPD
Interventions
Education (self-guided), Education (counselor-led), Physical Activity, Inhaler Training
Behavioral
Lead sponsor
Rush University Medical Center
Other
Eligibility
40 Years and older
Enrollment
448 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 22, 2025 · Synced Oct 8, 2026, 2:49 AM EDT